![\"la](\"https:\/\/www.aboutpharma.com\/wp-content\/uploads\/2018\/04\/reputation-e1522919268558-300x185.png\")
<\/figure>\nImprove the reputation of pharmaceutical companies globally. At least according to the latest report from the British research firm patient view,<\/a> which questioned 1,330 patient associations around the world. In 2017, 43% of the groups interviewed judged Big Pharma's reputation as "excellent" or "good", against 38% in 2016. At the top of the ranking, which includes 46 companies, we find two confirmations: VII Healthcare<\/strong> And Abbvie<\/strong>in first and second place respectively. On the third step, however, he arrives Gilead<\/strong>.<\/p>\n The survey, carried out between November 2017 and February 2018, evaluates the reputation of 46 pharmaceutical companies in relation to 12 key indicators, including integrity, transparency (on pricing policies, funding for stakeholders, clinical studies), patient centrality, ability to innovate and offer useful or high quality products.<\/p>\n Overall, the patient groups surveyed ranked the pharmaceutical sector third in terms of overall reputation out of nine healthcare domains, namely biotechnology, generics, health insurance, medical devices, private healthcare and pharmacies. In 2016, Big Pharma's reputation ranked fifth.<\/p>\n For the first time, Patient View introduced a question on the "net promoter score (NPS)" in the survey: patient groups that collaborated with companies were asked if they would recommend them to other patient groups. The highest scores were reported (in rank order) by these companies: Lundbeck, Ucb, Roche, ViiV Healthcare, Leo Pharma, Novo Nordisk, Novartis, Vertex Pharmaceuticals, Abbvie and Grifols.<\/p>\n Related news:\u00a0The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 75 Italian Patient Groups<\/span><\/a><\/p>\nThe reputation of Big Pharma<\/h2>\n
The top ten<\/h2>\n
![\"la](\"https:\/\/www.aboutpharma.com\/wp-content\/uploads\/2018\/04\/top-ten.jpg\")
<\/a>The Patien View ranking is based on responses from patient groups who report "familiarity" with the companies being researched. ViiV Healhtcare, also first this year, is at the top in almost all indicators (11 out of 12). Abbvie, on the second step of the podium, conquers the maximum evaluation in half of the indicators. Gilead, in third place, gains two positions compared to 2016. Novartis is in fourth place, followed by Janssen, Roche, Lundbeck, Ucb, Novo Nordisk and Pfizer.<\/p>\nThe net promotion score<\/h2>\n